12.56
-1.34%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangsu Kanion Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600557.SS. It has been listed since 18 September 2002. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.29bn and net income of CN¥303.9m. At that date it held total assets of CN¥6.86bn and shareholders' equity of CN¥4.82bn.
Jiangsu Kanion Pharmaceutical Co., Ltd. engages in the manufacturing and sale of Chinese patent medicine preparations and health products. The company is headquartered in Lianyungang, Jiangsu. The company went IPO on 2002-09-18. The firm provides capsules, oral liquid, granules, electuary, tablets, pills, patch and injections. The firm's products are applied in gynecology, orthopedics, cardiovascular and cerebrovascular, anti-infective, anti-tumor and others. The firm distributes its products mainly within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Sept 2002
- Employees
- 5,760
- Website
- kanion.com ↗
Leadership
Pay as last reported
- Mr. Wei XiaoChairman of the Board, since 2000CN¥2.4m
- Mr. Zhenzhong WangVice Chairman of the BoardCN¥1.0m
- Mr. Suocheng JiangChief Financial Officer, Director, since 2023CN¥207,500
- Mr. Yongchun YangGeneral Manager, Director, since 2007CN¥758,600
- Mr. Quan LiuDeputy General ManagerCN¥742,700
- Mr. Yu PanDeputy General ManagerCN¥1.1m
- Mr. Chuanlei WangDeputy General ManagerCN¥710,400
- Mr. Tuanjie WangDeputy General Manager
- Mr. Feipeng XianDeputy General ManagerCN¥521,100
- Mr. Peng PanSecretary of the Board
- Mr. Xuebin ChenDirectorCN¥641,100
- Mr. Haixin GaoDirector, since 2022CN¥1.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jiangsu Kanion Pharmaceutical employs 5,760 full-time employees in Lianyungang, CN.
- The company manufactures capsules, oral liquids, and tablets for gynecology and cardiovascular markets.
- Jiangsu Kanion's products include electuary, patches, and injections for anti-infective and anti-tumor applications.
Weaknesses
- Jiangsu Kanion's products are distributed mainly within domestic markets, limiting international reach.
- The company's business focuses on Chinese patent medicine preparations without global expansion.
- Jiangsu Kanion has no mention of international markets or foreign distribution channels.
Opportunities
- Jiangsu Kanion can expand into cardiovascular and cerebrovascular markets with its existing product lines.
- The company could leverage its 5,760 employees to develop new health products for domestic demand.
- Jiangsu Kanion may explore opportunities in anti-tumor and anti-infective segments for growth.
Threats
- Jiangsu Kanion faces competition from domestic pharmaceutical companies in China.
- The company's reliance on domestic markets exposes it to regional economic fluctuations.
- Jiangsu Kanion's product portfolio lacks international recognition or global market presence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.